Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cellectis Success With Off-The-Shelf CAR-T Threatens Kite, Juno, Novartis

This article was originally published in Scrip

Executive Summary

An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite, Juno and Novartis, may become commercially obsolete before they even reach the market.

You may also be interested in...

Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate

Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.

Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up

Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.

The Impact Of COVID-19 On Clinical Trials

Clinical trials for therapeutic areas aside from COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts